Forskning ved Københavns Universitet - Københavns Universitet

Forside

Rituximab (MabThera) til behandling af aktiv reumatoid artritis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Standard

Rituximab (MabThera) til behandling af aktiv reumatoid artritis. / El Fassi, Daniel; Nielsen, Claus Henrik; Bendtzen, Klaus.

I: Ugeskrift for Laeger, Bind 168, Nr. 47, 20.11.2006, s. 4079-81.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Harvard

El Fassi, D, Nielsen, CH & Bendtzen, K 2006, 'Rituximab (MabThera) til behandling af aktiv reumatoid artritis', Ugeskrift for Laeger, bind 168, nr. 47, s. 4079-81.

APA

El Fassi, D., Nielsen, C. H., & Bendtzen, K. (2006). Rituximab (MabThera) til behandling af aktiv reumatoid artritis. Ugeskrift for Laeger, 168(47), 4079-81.

Vancouver

El Fassi D, Nielsen CH, Bendtzen K. Rituximab (MabThera) til behandling af aktiv reumatoid artritis. Ugeskrift for Laeger. 2006 nov 20;168(47):4079-81.

Author

El Fassi, Daniel ; Nielsen, Claus Henrik ; Bendtzen, Klaus. / Rituximab (MabThera) til behandling af aktiv reumatoid artritis. I: Ugeskrift for Laeger. 2006 ; Bind 168, Nr. 47. s. 4079-81.

Bibtex

@article{467775af423746da83651e4aebdd17c3,
title = "Rituximab (MabThera) til behandling af aktiv reumatoid artritis",
abstract = "Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.",
author = "{El Fassi}, Daniel and Nielsen, {Claus Henrik} and Klaus Bendtzen",
year = "2006",
month = "11",
day = "20",
language = "Dansk",
volume = "168",
pages = "4079--81",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "47",

}

RIS

TY - JOUR

T1 - Rituximab (MabThera) til behandling af aktiv reumatoid artritis

AU - El Fassi, Daniel

AU - Nielsen, Claus Henrik

AU - Bendtzen, Klaus

PY - 2006/11/20

Y1 - 2006/11/20

N2 - Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.

AB - Rituximab (RTX) is a murine/human monoclonal antibody to CD20, a protein expressed almost exclusively on human B-lymphocytes. RTX induces rapid and marked B-cell depletion with beneficial clinical effects in 1/3 to 1/2 of rheumatoid arthritis patients. Treatment is given as two iv. infusions with a two-week interval and in combination with methotrexate. Mild to moderate side-effects are frequent, particularly during the first infusion, but long-term side-effects are generally rare, although pulmonary events and reactivation of viral infections of the liver is of concern.

M3 - Tidsskriftartikel

VL - 168

SP - 4079

EP - 4081

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 47

ER -

ID: 34072599